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Abstract
Background: The overexpression of eukaryotic translation initiation factor 4E (eIF4E), a key
regulator of protein synthesis, is involved in the malignant progression of human breast cancer. This
study investigates the relationship between eIF4E and angiogenesis, as well as their prognostic
impact in patients with human breast cancer.
Methods: Immunohistochemical staining was used to determine protein expression of eIF4E,
vascular endothelial growth factor (VEGF), interleukin-8 (IL-8), and CD105 in a set of 122 formalin-
fixed, paraffin-embedded primary breast cancer tissues. Expression of eIF4E in positive cells was
characterized by cytoplasmic staining. Evaluation of VEGF and IL-8 in the same tissue established
the angiogenic profiles, while CD105 was used as an indicator of microvessel density (MVD).
Results: A significant relationship was found between the level of eIF4E expression and histological
grade (P = 0.016). VEGF, IL-8, and MVD were closely related to tumor grade (P = 0.003, P = 0.022,
and P < 0.001, respectively) and clinical stage (P = 0.007, P = 0.048, and P < 0.001, respectively).
Expression of eIF4E was also significantly correlated with VEGF (P = 0.007), IL-8 (P = 0.007), and
MVD (P = 0.006). Patients overexpressing eIF4E had significantly worse overall (P = 0.01) and
disease-free survival (P = 0.006). When eIF4E, histological grade, tumor stage, ER, PR, Her-2 status
and the levels of VEGF, IL-8, MVD were included in a multivariate Cox regression analysis, eIF4E
emerged as an independent prognostic factor for breast cancer (P = 0.001), along with stage (P =
0.005), node status (P = 0.046), and MVD (P = 0.004).
Conclusion: These results suggest that higher eIF4E expression correlates with both angiogenesis
and vascular invasion of cancer cells, and could therefore serve as a useful histological predictor for
less favorable outcome in breast cancer patients, as well as represent a potential therapeutic target.
Background
Angiogenesis, which is essential for both tumor growth
and metastasis, depends on the production of angiogenic
factors by tumor cells and normal cells. Several pathways
are involved, including those involved with the secretion
of angiogenic substances, activation of endothelial cells,
degradation of capillary membranes, and endothelial cell
migration. The resulting increased vascularity enhances
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greater chance for hematogenous metastasis [1]. At the
beginning of this undesirable angiogenic process, two
potent angiogenic growth factors, VEGF and IL-8, are
known to stimulate endothelial cell proliferation, induce
microvessel permeability, and begin to establish the
tumor neovasculature [2]. Disruption of the capacity to
produce or upregulate these factors should help to control
the progression of cancer.
VEGF, a well-known contributor to angiogenic processes
in breast cancer, exhibits an increase in expression during
pre-invasive cancer progression and is significantly associ-
ated with high intratumoral microvessel density [3-6]. The
level of VEGF expression independently predicts disease-
free survival (DFS) and overall survival (OS) in invasive
breast carcinoma [7,8].
IL-8, a CXC chemokine originally identified as a neu-
trophil chemotactic factor, was subsequently recognized
to have many functions that promote tumor growth, ang-
iogenesis, and metastasis [9]. It is released by both stromal
cells and tumor-associated macrophages in the tumor
microenvironment, and is considered to have pro-ang-
iogenic and pro-malignant effects [10]. Recently, it has
been shown that an elevated level of IL-8 expression in
breast cancer is accompanied by a high level of VEGF
expression [11]. In addition, high level of IL-8 expression
is associated with the invasive potential of breast cancer
cells [12].
Up-regulation of angiogenic growth factor synthesis is
directly related to mediation of transcriptional and trans-
lational events. One of the major translation factors,
eIF4E, plays a key role in cellular protein synthesis. It is a
25 kD protein that recognizes the 7-methylguanosine-
containing cap at the 5-prime terminus of mRNA, and it
assists in the transfer of mRNA to the 48S ribosomal com-
plex. By binding to this cap, eIF4E facilitates the attach-
ment of the "RNA helicase complex," known as eIF4F
[13]. A number of observations suggest that increased
expression of eIF4E might be one of the key elements
leading to angiogenesis, which ultimately results in tumor
metastasis [14]. Recently, McClusky et al. suggested that
eIF4E is strongly involved in increasing the risk for tumor
recurrence and in a poor prognosis for patients with node-
positive breast cancer [15]. In the present study, we have
examined this possibility as well as furthered the investi-
gation into eIF4E's relationship to angiogenesis, by testing
biopsies from a large sample of patients with untreated
breast cancer.
Our findings suggest that eIF4E expression is closely
related to IL-8 and VEGF expression in breast cancer cells,
possibly contributing to disease progression. We strongly
believe that identification of mediators of translation such
as eIF4E may enable future design of therapeutic modali-
ties that can jointly target several pro-malignancy factors
at once. Histological testing for these factors would
indeed be useful in assessing patient risk, but translation
of this knowledge into therapy would be even more use-
ful. Implementation of a therapeutic approach that
includes control of angiogenesis is more likely to lead to
improved treatment outcomes for all breast cancer
patients, including those at higher risk.
Methods
The collection of tissue samples from breast cancer 
patients
Tissue samples were studied from 122 breast carcinoma
patients ranging from 41 to 77 years of age (median age,
56.2 years), who had not received chemotherapy, radio-
therapy, or hormone therapy prior to surgery. All patients
were treated at the Department of Surgery in Tongji Hos-
pital (Huazhong University of Science and Technology,
Wuhan, China) and were sequential cases seen from
October 1996 to July 1999. These select untreated breast
cancer patients underwent axillary node excision com-
bined with wide local excision with margin clearance or
mastectomy. Study samples were collected at this time.
Adjuvant axillary irradiation, systemic chemotherapy, and
antiestrogen therapy were then offered and administered
as indicated per current post-surgical standard of care.
Patient follow-up ranged from 1–72 months (median, 44
months): Clinical records show that 77 patients were
found to be disease-free, while 45 breast cancer patients
relapsed, of whom 30 subsequently died. The 5-year sur-
vival rate was 76.4%. Mean survival time was 41.89 ± 8.38
months and median survival time was 39 months. Overall
patient survival was calculated as the period from surgery
until the date of death, while disease-free survival was the
period from surgery to date of metastasis.
The research protocol was approved by our Institutional
Review Board (IRB) before all specimens were examined
by experienced pathologists. Histological examination
was carried out on paraffin-embedded sections stained
with hematoxylin & eosin (H&E). These specimens had a
spectrum of breast carcinomas represented, including 80
invasive ductal carcinomas (IDC), 15 ductal carcinomas
in situ (DCIS), and 5 lobular carcinomas in situ (LCIS). In
addition, special invasive carcinoma types included: 14
invasive lobular carcinomas (ILC), 6 medullary carcino-
mas (MC), and 2 tubular carcinomas (TC). The 102 inva-
sive carcinoma cases seen included 27 welldifferentiated
(grade I), 41 moderately differentiated (grade II), and 34
poorly differentiated (grade III) carcinomas. Similarly,
there were 5 low-grade, 3 intermediate-grade, and 12
high-grade cases in the non-invasive carcinomas (DCIS
and LCIS). Tumor size varied from 0.5 to 6.8 cm (mean,Page 2 of 12
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74 patients had experienced lymph node metastases.
Other clinical and pathologic parameters were obtained
from the hospital pathology reports, including estrogen
receptor (ER) and progesterone receptor (PR) status,
Her2/neu status, and the TNM stage (Table 1).
Immunohistochemistry for eIF4E
The paraffin-embedded, formalin-fixed archival breast tis-
sue was cut into four-micrometer sections and fixed on
charged slides using heat immobilization, by baking at
60°C for 2 hours. The slides were then deparaffinized in
xylene and subsequently rehydrated through a graded eth-
anol series ending in deionized water. Any endogenous
peroxidase was blocked by treatment with 3% hydrogen
peroxide for 15 minutes, followed by 3 rinses of 5 minutes
each in deionized water. Antigen retrieval was performed
by placing slides in 1× citrate buffer for 15 minutes at
100°C (in a microwave). The eIF4E primary antibody
(Santa Cruz, California, USA), diluted to 1:100 in phos-
phate-buffered saline (PBS) and 1% bovine serum albu-
min, was left on tissue overnight at 4°C, in a humidified
chamber. As a negative control, preimmune serum was
substituted for the primary antibody. All sections were
rinsed in PBS 3 times, 5 minutes each. Secondary anti-
body (Envison, Anti-Mouse/Rabbit-HRP, DAKO) was
applied to all sections and incubated for 30 minutes at
room temperature (RT), followed by 3 PBS rinses of 5
minutes each. Finally, the sections were developed with
3,3'-diaminobenzidine (DAB) for 5 minutes at RT, then
counterstained with hematoxylin. After staining, sections
were dehydrated through a graded series of ethanol baths
followed by xylene and cover-slipped. Using microscopy,
the section's tumor cell immunoreactivity for eIF4E was
scored according to the cytoplasmic staining present: Both
the percentage of positively stained tumor cells and the
stain intensity were taken into account to determine eIF4E
expression values. The percentage of positive cells was
rated as follows: 1 point, <5% positive tumor cells; 2
points, 5–25% positive cells; 3 points, 26–75% positive
cells; and 4 points, >75% positive cells. Stain intensity was
rated as follows: 1 point, weak intensity; 2 points, moder-
ate intensity; and 3 points, strong intensity. The breast
cancer specimens were attributed to four groups, accord-
ing to their overall score: Absent expression, when <5% of
cells stained positive, regardless of intensity; weak expres-
sion, a total of 3 points; moderate expression, 4–5 points;
and strong expression, 6–7 points. For statistical reasons,
tumors were then scored according to a two-scale system:
Low reactivity denoting tumors with absent or weak
expression, and high reactivity denoting tumors with
moderate to strong expression. The association of eIF4E
with other parameters was assessed using eIF4E as either a
categorical variable (low reactivity vs. high reactivity) or a
continuous variable (the percentage of eIF4E-positive
cells within a sample).
VEGF and IL-8 detection and assessment
VEGF and IL-8 expression were assessed using purified
mouse anti-human monoclonal antibodies (purchased
from Santa Cruz, California, USA), diluted 1:100 and
1:50, respectively, in an overnight incubation, following
Table 1: Clinical characteristics
Variable No. of patients (%)
Total 122 (100%)
Age (median, 56 years)
<56 years 68 (55.7%)
≥56 years 54 (44.3%)
Surgical treatment
Breast conservation 29 (23.8%)
Mastectomy 93 (76.2%)
Tumor size (mean, 3.1 cm)
<3.1 cm 70 (57.4%)
≥3.1 cm 52 (42.6%)
Histological diagnosis









Invasive carcinoma 102 (83.6%)
Grade I 27 (22.1%)
Grade II 41 (33.6%)
Grade III 34 (27.9%)
Non invasive carcinoma 20 (16.4%)
Low grade 5 (4.1%)
Intermediate grade 3 (2.5%)
High grade 12 (9.8%)
TNM staging
Stage I 30 (24.6%)
Stage II 33 (27.1%)
Stage III 37 (30.3%)














Disease free 77 (63.1%)
Metastasis or recurrence 45 (36.9%)
Died for breast cancer 30 (24.6%)Page 3 of 12
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centage of cancer cells having cytoplasmic staining for
VEGF or IL-8 reactivity was recorded. Staining was graded
in a four-grade classification as follows: -, for those where
reactivity was not detected; 1+, those with positive stain in
less than 5% of tumor cells; 2+, a positive stain between
5% and 50%; and 3+, when greater than 50% positive.
The median value was used as a cut-off point to define
those tumors having either high or low reactivity for VEGF
and IL-8.
Evaluation of microvessel density
Tumor angiogenesis was assessed by calculating standard
microvessel density (MVD). Microvessels were identified
by immunostaining endothelial cells with the mouse anti-
human monoclonal antibody CD105, which targets the
receptor for the transforming growth factor beta 1 (TGFβ-
1). Although the TGFβ-1 receptor has weak or negative
expression in the vascular endothelium of normal human
tissues, it is more specific and sensitive in the vascular
endothelium of cancer tissues [16]. First, each slide was
scanned at low magnification (×100) to identify four
areas with the highest density of microvessels
("hotspots"). Each hotspot was then evaluated at high
power magnification (×400) for the number of stained
microvessels per field. Any endothelial cell having a
brown stain was considered to be a single countable
microvessel, and the presence of a clearly defined vessel
lumen was not required to verify the structure. The final
microvessel score was the average of vessel counts from
four fields. MVD was quoted as a continuous variable.
Statistical analysis
One-way ANOVA testing was used to assess correlations
between the continuous variables. Contingency tables
were analyzed for trends with the chi-square test, in order
to evaluate differences in clinicopathologic factors
between the patient groups. The Spearman rank correla-
tion coefficient test was used to examine the correlations
between different variables. Linear regression analysis was
also used to assess the correlation between continuous
variables. Survival curves were plotted using the method
of Kaplan and Meier and the significance of the observed
differences was assessed using the log-rank test. Survival
analysis was carried out using either cancer recurrence or
death from disease as the endpoints for disease-free sur-
vival (DFS) and overall survival (OS), respectively. The
influence of each variable on survival was assessed with
the Cox proportional hazards regression model. The level
of statistical significance was defined as P < 0.05. All anal-
yses were carried out using SPSS 11.0 for Windows 2000
software.
Results
Immunochemical staining of eIF4E, VEGF, IL-8, and CD105 
in breast cancer tissue
In breast carcinoma, localization of eIF4E protein overex-
pression was mainly cytoplasmic in the cancer cells, but
not in the adjacent normal-looking ductal epithelial cells
and stromal elements. Of 122 tumors, 59 (48.4%)
showed low reactivity (absent or weak expression) and 63
(51.6%) showed high reactivity (moderate to strong
expression) (Fig. 1A,B, and 1C). Immunopositive reac-
tions for VEGF (Fig. 1D,E and 1F) and IL-8 (Fig. 1G,H and
1I) were confined to the cytoplasm of cancer cells. Expres-
sion of VEGF was found to be negative, weak, moderate,
and strong in 29 (23.8%), 38 (31.1%), 34 (27.9%), and
21 (17.2%) tumor tissues, respectively. Also, the IL-8 pro-
tein showed negative, weak, moderate, and strong stain-
ing in 21 (17.2%), 40 (32.8%), 37 (30.3%) and 24
(19.7%) of 122 tumors, respectively. In addition, it was
evident that both VEGF and IL-8 had higher immunoreac-
tivity in the IDC than in the DCIS. In a few specimens, the
most intense reaction was demonstrated distal to the
blood vessels and surrounding necrotic areas, but in the
vast majority of positive cancer cells we observed a diffuse
expression pattern that was independent of vessel proxim-
ity.
Vascular endothelial cell or endothelial cell clustering
around the tumors was evident using the anti-CD105
antibody (Fig. 1J,K and 1L). The mean value of MVD was
found to be 15.22 ± 6.93. The microvessels around the
solid tumor nest were much denser than those in the adja-
cent normal tissues.
Correlation of eIF4E, VEGF, IL-8, and MVD with 
clinicopathologic parameters
A significant positive association between eIF4E immuno-
reactivity and the histological grade of the invasive tumor
was found (p = 0.016). In addition, we found that invasive
carcinoma was different from non-invasive carcinoma
with respect to eIF4E immunostaining (p = 0.034). No sig-
nificant correlations occurred between eIF4E expression
and patients' age (p = 0.49), histological type in invasive
carcinoma (p = 0.72), tumor size (p = 0.25), node metas-
tasis (p = 0.23), TNM stage (p = 0.54), or the ER, PR, and
HER-2 status provided (p = 0.44, p = 0.38, and p = 0.45,
respectively) (Table 2). In addition, we found that VEGF
and IL-8 were closely related to both the tumor grade (p =
0.003 and p = 0.022, respectively) and the clinical stage (p
= 0.007 and p = 0.048, respectively) (Table 3). Increasing
MVD was also linked with increasing tumor grade (p <
0.001) and stage (p < 0.001) (Table 4).
Correlation of eIF4E with angiogenesis markers
Using the Spearman rank correlation, significant correla-
tions of eIF4E with both VEGF (p = 0.007, r = 0.316) andPage 4 of 12
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Representatives of immunohistochemical staining for eIF4E, VEGF, IL-8 and CD105 expression in breast cancerFigure 1
Representatives of immunohistochemical staining for eIF4E, VEGF, IL-8 and CD105 expression in breast cancer. A, slide for 
eIF4E expression in the adjacent normal ductal epithelial cells (negative), B, eIF4E expression in the cytoplasm of tumor cells of 
ductal carcinomas in situ (moderate positive), C, eIF4E expression in invasive ductal carcinoma cells (strong positive); D-F and 
G-I, representative panels for VEGF and IL-8 expression, respectively, in 3 types of tissues as detected for eIF4E expression in 
(A-C); J-L, representative slides for positive CD105 expression in 3 breast cancer specimens with invasive ductal carcinoma 
(×200).
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noted (Fig. 2A,2B). Using linear regression analysis, we
studied the association of the percentage of tumor cells
staining positive for eIF4E and MVD. We found a signifi-
cant correlation between the proportion of eIF4E-positive
cells and MVD (p = 0.006, r = 0.34) in these breast cancer
samples (Fig. 3).
Survival analysis
The Kaplan-Meier survival curves for eIF4E, VEGF, and IL-
8 (Fig. 4) demonstrated that when the survival of breast
cancer patients having moderate to strong expression of
eIF4E is compared with the survival of patients with
absent to weak expression of eIF4E through log-rank test-
ing, there was a significantly unfavorable influence for
eIF4E expression on both the overall survival (OS) (p =
0.01) and disease-free survival (DFS) (p = 0.006) of the
patients (Fig. 4A,B). Univariate analysis revealed that
overexpression of VEGF and IL-8 were also associated with
a worse prognosis, with both unfavorable OS (p = 0.02
and p = 0.03, respectively) and DFS (p = 0.01 and p = 0.02,
respectively) linked to these two pro-angiogenic growth
factors as well (Fig. 4C–F).
Multivariate analysis
To examine the independent prognostic significance of
eIF4E in relation to the classical clinicopathological
parameters and angiogenic variables, multivariate analy-
sis of OS was performed including eIF4E and all three ang-
iogenic markers, as well as other risk factors such as tumor
Table 2: Correlations of eIF4E with clinicopathological parameters
eIF4E expression
Variable n Low reactivity High reactivity p value
n % n %
Total 122 59 48.4 63 51.6
Age (median, 56 years)
<56 years 68 31 25.4 37 30.3 0.49
≥ 56 years 54 28 23.0 26 21.3
Tumor size
<3.1 cm 70 37 30.3 33 27.0 0.25
≥3.1 cm 52 22 18.1 30 24.6
Histological diagnosis
Invasive carcinoma 102 45 36.9 57 46.7 0.034
Non invasive carcinoma 20 14 11.5 6 4.9
Invasive carcinoma type
Ductal 80 34 33.3 46 45.1 0.72
Lobular 14 8 7.8 6 5.9
Medullary 6 2 2.0 4 3.9
Tubular 2 1 1.0 1 1.0
Invasive carcinoma grade
Grade I 27 17 16.7 10 9.8 0.016
Grade II 41 19 18.6 22 21.6
Grade III 34 9 8.8 25 24.5
TNM staging
Stage I 30 16 13.1 14 11.5 0.54
Stage II 33 18 14.8 15 12.3
Stage III 37 17 13.9 20 16.4
Stage IV 22 8 6.6 14 11.4
Node metastatic status
Negative 48 20 16.4 28 22.9 0.23
Positive 74 39 32.0 35 28.7
ER status
Negative 54 24 19.7 30 24.6 0.44
Positive 68 35 28.7 33 27.0
PR status
Negative 65 29 23.8 36 29.5 0.38
Positive 57 30 24.6 27 22.1
Her-2/neu status
Negative 66 34 27.9 32 26.2 0.45
Positive 56 25 20.5 31 25.4Page 6 of 12
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a multivariate model that included tumor grade, stage and
the ER, PR, and Her-2 status, as well as levels of VEGF, IL-
8, MVD, and eIF4E found in the tissues; eIF4E emerged as
an independent prognostic factor for OS (p = 0.001),
along with stage (P = 0.005), node status (P = 0.046), and
the MVD present (P = 0.004). Table 6 shows the results of
the multivariate analysis of DFS including the previously
mentioned parameters. The eIF4E, MVD, and tumor stage
still emerged as independent prognostic factors (p = 0.02,
p = 0.011, and p = 0.048, respectively), but node metasta-
sis was found to be of borderline significance (p = 0.062).
Discussion
The initiation of protein translation is now recognized as
an important step in the control of gene expression. In
eukaryotic cells, most mRNAs are translated through a
cap-dependent mechanism of initiation. As a cap-binding
protein, eIF4E plays a central role in this process [17,18].
This eIF4E protein was first shown to be overexpressed in
breast cancer by Kerekatte et al [19]. Later studies by Li et
al [20,21] have demonstrated that the degree of eIF4E
overexpression predicts cancer recurrence and outcome in
stage I to III breast cancer patients. Cancer specimens
exhibiting high levels of eIF4E expression increase the
patient's relative risk for cancer recurrence as compared to
patient cancer specimens with low eIF4E expression. It has
been noted that eIF4E overexpression is associated with
tumor angiogenesis in breast cancer [22]. A recent report
by Byrnes et al [23] further showed that increasing eIF4E
overexpression in breast cancer correlates with MVD
counts as well as high VEGF levels. Thus, it appeared that
there might be significant relationships between the over-
expression of eIF4E, angiogenesis, cancer recurrence, and
patient survival in breast cancer.
In the present study, we examine the level of expression of
eIF4E in order to analyze any correlations with the mole-
cules initiating angiogenic pathways and patient progno-
sis, using histological samples from a relatively large
number of patients with previously untreated breast can-
cer. Here we have shown that eIF4E, as revealed by immu-
nohistochemistry, is overexpressed in breast cancer tissue.
Indeed, a strong association of eIF4E with an angiogenic
Table 3: VEGF and IL-8 in relation to clinicopathological indicators and eIF4E reactivity
Variable VEGF p value IL-8 p value
(-) (1+) (2+) (3+) (-) (1+) (2+) (3+)
Total 29 38 34 21 21 40 37 24
Age (median, 56 years)
<56 years 13 21 17 8 0.43 13 18 24 11 0.24
≥56 years 16 17 27 13 8 22 13 13
Tumor size
<3.1 cm 20 20 15 7 0.09 15 20 14 10 0.08
≥3.1 cm 9 18 10 14 6 20 23
Invasive carcinoma grade
Grade I 14 19 8 2 0.003 10 17 8 2 0.022
Grade II 10 12 12 6 6 13 11 9
Grade III 5 7 14 13 5 10 18 13
TNM staging
Stage I 10 14 7 1 0.007 9 13 6 3 0.048
Stage II 9 10 9 3 6 14 10 4
Stage III 7 8 8 4 3 8 9 6
Stage IV 3 6 10 13 3 5 12 11
eIF4E expression
Low reactivity 20 18 17 4 0.007 15 19 20 5 0.007
High reactivity 9 20 17 17 6 21 17 19
Table 4: MVD with tumor grade, stage and eIF4E expression
Variable n MVD p value
(mean ± S.D.) (ANOVA)
Total 122 15.22 ± 6.93
Invasive carcinoma grade
Grade I 27 10.63 ± 7.54 p < 0.001
Grade II 41 14.98 ± 5.72
Grade III 34 18.36 ± 6.01
TNM staging
Stage I 30 10.55 ± 5.36 p < 0.001
Stage II 33 12.42 ± 6.17
Stage III 37 15.62 ± 4.75
Stage IV 22 25.11 ± 5.62
eIF4E expression
Low reactivity 59 10.19 ± 7.02 p < 0.001
High reactivity 63 19.93 ± 6.89Page 7 of 12
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sistent with the observation from the study in patients
with stage I to III breast cancer by Byrnes et al [23], our
results studied in all stages including stage IV breast cancer
patients demonstrated that eIF4E overexpression is associ-
ated with high levels of VEGF and MVD counts. In addi-
tion, we found that eIF4E overexpression is associated
with increased IL-8 expression. Both VEGF and IL-8
expression are up-regulated in breast cancer tissue, most
likely triggering the neoangiogenesis process, which is
Linear regression analysis of the percentage of eIF4E positively stained cells with MVDFigu e 3
Linear regression analysis of the percentage of eIF4E positively stained cells with MVD.
Graphical representation for analysis of the correlation between eIF4E expression and VEGF levels (A) as well as with IL8 expression (B) in breast cancerFigure 2
Graphical representation for analysis of the correlation between eIF4E expression and VEGF levels (A) as well as with IL8 
expression (B) in breast cancer.Page 8 of 12
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tions are indicative of a role for eIF4E as a key regulator of
the angiogenic cascade. In support of our premise, we
found that both VEGF and IL-8 upregulation are associ-
ated with increased MVD.
Furthermore, we also observed that there is an increase in
tumor-associated VEGF and IL-8 in patients with unfavo-
rable prognoses. The unfavorable influence of VEGF and
MVD on breast cancer outcome has previously been
reported [24]. In that study, high VEGF expression and,
consequently, enhanced angiogenic effect are found to
offer the malignant cells the ability to implant, grow rap-
idly, and possibly interfere with the immune response
among malignant cells, therefore leading to tumor relapse
or facilitating invasion and stage progression. We believe
that a potential linkage of high eIF4E expression results in
the upregulation of angiogenic factors such as VEGF, cre-
ating the subsequent increase in tumor MVD and a worse
clinical outcome. Our survival analysis for each of the fac-
tors we suspect may lead to cancer progression and nega-
tive clinical outcomes demonstrated that patients with
lower eIF4E expression had a statistically significant lower
rate of cancer recurrence, when compared with those
patients with higher eIF4E expression (p = 0.006, log-rank
test). Similarly, we found that patients with higher eIF4E
expression had higher mortality than those patients with
lower eIF4E expression (p = 0.01, log-rank test).
An interesting observation was the fact that when eIF4E
was included with grade, stage, MVD, VEGF, and IL-8
expression in the multivariate model, it had an independ-
ent negative prognostic effect on overall and disease-free
survival (P = 0.001 and P = 0.02, respectively). Our results
did not show correlations of eIF4E expression with nodal
status and expression of ER, PR and Her-2/neu. Although
nodal status is believed the most important prognostica-
tor for breast cancer outcome, our study indicated a "bor-
derline significance" for overall and disease-free survival
(P = 0.046 and P = 0.062, respectively). In a prospective
study designed to specifically address risk for recurrence in
patients with node-positive breast cancer, eIF4E overex-
pression appears to be an independent predictor of a
worse outcome independent of nodal status [15]. Based
on the previous observation and our results, we hypothe-
size that eIF4E overexpression is likely more important
than nodal status in predicting breast cancer recurrence
and outcome.
The overexpression of eIF4E would be responsible for ini-
tiating the translation of many polypeptides, including
the angiogenic and growth-promoting factors included in
this study. Since some of these latter factors would make
cancer cells become more proliferative and invasive, our
findings may explain the significant association of vascu-
lar invasion and a worsened clinical outcome in patients
having marked eIF4E expression.
Conclusion
In conclusion, the results of this study provide evidence
that the immunohistochemical level of eIF4E expression
is markedly upregulated in high-grade invasive breast can-
cer tissues. In addition, we found that overexpression of
eIF4E might play an important role in tumor progression
and microneoangiogenesis. Specifically, our findings
show that eIF4E may be an important regulator of produc-
tion of angiogenic factors, such as IL-8 and VEGF that are
associated with poor prognosis in breast cancer. We
believe that eIF4E could be a potential target for adjuvant
therapy and that it might even substantially enhance the
effects of radiation and chemotherapy. The role of eIF4E
as a viable target to block the development of angiogen-
esis and advanced breast cancer deserves further investiga-
tion.
Table 5: Cox hazard estimation of OS in breast cancer (Multivariate analyses)
Parameter Regression 
Coefficient
Standard Error Wald Relative Risk 95% CI P value
Lower Upper
Tumor size 2.749 1.622 2.872 2.572 0.515 2.347 0.098
Node status -0.807 0.376 4.602 0.446 0.213 0.933 0.046
Stage 0.529 0.189 7.851 1.697 1.172 2.456 0.005
Grade 0.237 0.289 0.118 1.332 0.72 2.232 0.412
ER 0.463 0.489 0.896 1.589 0.609 4.143 0.344
PR 0.226 0.363 0.388 1.253 0.616 2.551 0.533
Her-2 0.263 0.412 0.406 1.301 0.58 2.918 0.524
IL-8 0.383 0.36 1.134 1.467 0.725 2.969 0.287
MVD 0.195 0.068 8.2 1.215 1.063 1.388 0.004
VEGF 0.257 0.411 0.39 1.293 0.578 2.892 0.532
eIF4E 2.232 0.644 12.021 9.316 2.638 32.896 0.001Page 9 of 12
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Comparison of overall as well as disease-free survival using the Kaplan-Meier analysis between the groups of patients with low 
and high eIF4E, VEGF and IL-8 protein expression.
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